English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 31 July 2023, 20:00 HKT/SGT
Share:
    

Source: China Medical System Holdings Ltd.
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management

SHENZHEN, CHINA, July 31, 2023 - (ACN Newswire) - Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.

MSCI is one of the most widely used, influential, and referenced rating companies in the global market. Based on a scientifically rigorous evaluation system, it evaluates companies' risk control performance and sustainable development potential comprehensively from various aspects such as environment, human capital, health accessibility, product safety and quality, and corporate governance. MSCI-ESG rating results have been regarded by global investors as an important non-financial basis for investment decision-making. Being back to the "AA" rating, reflects the full recognition of the Group's ESG management practices by the international authoritative rating company.

The Group deeply integrates the concept of sustainable development into its operations with a development perspective, continuously improves its internal governance under the guidance of its ESG strategy, and actively assumes its responsibilities as a corporate citizen. Based on years of continuous investment in sustainable development, CMS's ESG management has been widely recognized: over the past three years, the Group's MSCI-ESG rating has maintained an "A" or "AA; its S&P Global ESG score surpassed 92% of the global peers with a score of 53, and successfully stood out from approximately 1,600 Chinese companies to be included in the first "Sustainability Yearbook (China)" of S&P Global.

In the future, CMS will always keep in mind its mission of being a responsible citizen, and work together with its stakeholders to promote healthy, harmonious, and sustainable development of the industry, society, and environment.

About CMS:

CMS (0867.HK) is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet healthcare needs.

CMS focuses on developing first- or best-in-class innovative products and has made the layout of 30 differentiated pipeline products with strong market potential. CMS deeply engages in specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to strengthen the competitiveness of its cardio-cerebrovascular/gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business, whilst enhancing the scale and efficiency. CMS also entered into the Southeast Asian market to create new opportunities to further enhance the sustainable development of the Group.

Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

Topic: Press release summary
Source: China Medical System Holdings Ltd.

Sectors: Healthcare & Pharm, MedTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

China Medical System Holdings Ltd. Related News
2024年9月24日 22時00分 JST
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
Sept 24, 2024 21:20 HKT/SGT
康哲药业:磷酸芦可替尼乳膏(白癜风)中国上市许可申请已获受理
Sept 24, 2024 21:00 HKT/SGT
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
Aug 16, 2024 16:42 HKT/SGT
康哲藥業(00867)發佈2024年中期業績:營業額和利潤環比均穩步提升
Aug 16, 2024 16:24 HKT/SGT
康哲药业(00867)发布2024年中期业绩:营业额和利润环比均稳步提升
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575